Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. - Wenzl K; Stokes ME; Novak JP; Bock AM; Khan S; Hopper MA; Krull JE; Dropik AR; Walker JS; Sarangi V; Mwangi R; Ortiz M; et al. (Blood cancer journal, 2024)